Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
65k av ~95p
In the real world these sort of companies are very few are far between (on this scale);
A - Valued at a fraction of, the sum of the parts
B - Can be broken up easily
C - Have potential buyers for the all business franchises
D - Able to make an easy 30% margin after paying North of £2 per share
Hell if I had the cash myself, I would be tempted
Wildtiger, mate you are going to have to do a lot better than that. I dont think 100 neg comments will stop a takeover/buyout...Are you for real...haha
Yeah that GIF was disturbing and I found myself looking at it, very off putting
Lets be honest the takeout price is likely SOTP valuation - 20% give or take, so ~£2
https://www.washingtonpost.com/business/2023/04/18/will-apollo-offer-thg-a-route-out-of-its-troubles/b335e6d2-dd9f-11ed-a78e-9a7c2418b00c_story.html
Re posed as url gets lost in other threads
He just says it as he sees it.....called democracy
Is there any credence to the £1.25 offer
results are expected to be poor as loses grow, this has been well sign posted
Its all about the "takeover", it will be end of days for THG very soon
US private equity giant Apollo swoops on Hut Group: Shares in the troubled online retailer soar 50% as takeover fever grips the City......
Are punters seriously seeing this North of £2
Cannot see a bid North of £2
- No funding until mid 24
- Global Frontier Partners increased stake a few weeks back by ~2% last month
- Massive moat, no direct competition with FDA approval
- Ovarian cancer study delivering best in class results, far out-performing standard of care for the detection of ovarian cancer demonstrating the value of the Parsortix® system in the real-world
- Progressing with Prostate cancer studies utilising the Parsortix system in collaboration with Solaris Health Holdings. Studies expected to complete 2023 with Solaris marketing a Parsortix prostate cancer test to its patient base of over 729,000 patients annually.
- Strong position to play a leading role in emerging US$ 100 billion dollar liquid biopsy market for personalised cancer care
- 2 heavy weight hitters joined the team AGL and now has the resources in place to deliver on its strategic and commercial plans
- Pipeline of global opportunities growing strongly, engagement with major pharma companies, medtech companies and clinical laboratories.
The list goes on.....Feels like a fair risk reward trade of these levels